Expression of NF-κb p50 in tumor stroma limits the control of tumors by radiation therapy

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Crittenden, Marka R ^a,b   Cottam, Benjamin ^a   Savage, Talicia ^a   Nguyen, Cynthia ^a   Newell, Pippa ^a   Gough, Michael J ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Oregon Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CELL TRANSPORT; CONTROLLED STUDY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MACROPHAGE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; POLARIZATION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS; NF-KAPPA B P50 SUBUNIT;

MUS;

EID: 84862976444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039295     Document Type: Article

References (52)

1. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, et al. (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114: 589-595.
2. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, et al. (1998) Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4: 581-587.
3. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, et al. (2010) Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother 33: 798-809.
4. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, et al. (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11: 728-734.
5. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890-898.
6. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
7. Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, et al. (2001) Macrophages orchestrate the immune response to tumor cell death. Cancer Res 61: 7240-7247.
8. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
9. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
10. Huynh ML, Fadok VA, Henson PM, (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41-50.
11. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, et al. (2009) Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 113: 5650-5659.
12. Filippi CM, von Herrath MG, (2008) IL-10 and the resolution of infections. J Pathol 214: 224-230.
13. Sica A, Schioppa T, Mantovani A, Allavena P, (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
14. Lin EY, Li JF, Bricard G, Wang W, Deng Y, et al. (2007) Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1: 288-302.
15. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, et al. (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116: 2777-2790.
16. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, et al. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64: 5839-5849.
17. Ralph P, Nakoinz I, (1977) Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. Journal of Immunology 119: 950-954.
18. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Research 52: 1399-1405.
19. Priebe TS, Atkinson EN, Pan BF, Nelson JA, (1992) Intrinsic resistance to anticancer agents in the murine pancreatic adenocarcinoma PANC02. Cancer Chemother Pharmacol 29: 485-489.
20. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, et al. (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68: 5206-5215.
21. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, et al. (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4: e6562.
22. Murray PJ, Wynn TA, (2011) Protective and pathogenic functions of macrophage subsets. Nature reviews Immunology 11: 723-737.
23. Drutman SB, Kendall JC, Trombetta ES, (2012) Inflammatory Spleen Monocytes Can Upregulate CD11c Expression Without Converting into Dendritic Cells. Journal of Immunology.
24. Jia T, Serbina NV, Brandl K, Zhong MX, Leiner IM, et al. (2008) Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. Journal of Immunology 180: 6846-6853.
25. Lu H, Huang D, Ransohoff RM, Zhou L, (2011) Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25: 3344-3355.
26. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, et al. (2001) Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411: 207-211.
27. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, et al. (2003) L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 171: 1232-1239.
28. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, et al. (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64: 4328-4337.
29. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, et al. (2008) Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181: 3099-3107.
30. Bursuker I, North RJ, (1984) Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 159: 1312-1321.
31. Sica A, Bronte V, (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
32. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202: 885-891.
33. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, et al. (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57: 4036-4041.
34. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, et al. (2007) Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13: 1493-1502.
35. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ, (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62: 1462-1470.
36. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72: 3666-3670.
37. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, et al. (1996) Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 56: 4311-4314.
38. Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, et al. (1998) Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43: 575-577.
39. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, et al. (2003) IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 102: 4123-4129.
40. Halak BK, Maguire HC Jr, Lattime EC, (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59: 911-917.
41. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP, (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446.
42. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, et al. (2010) Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 70: 5679-5685.
43. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, et al. (2010) Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 107: 8363-8368.
44. Colombo MP, Mantovani A, (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65: 9113-9116.
45. Mizgerd JP, Lupa MM, Kogan MS, Warren HB, Kobzik L, et al. (2003) Nuclear factor-kappaB p50 limits inflammation and prevents lung injury during Escherichia coli pneumonia. Am J Respir Crit Care Med 168: 810-817.
46. Oakley F, Mann J, Nailard S, Smart DE, Mungalsingh N, et al. (2005) Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. The American journal of pathology 166: 695-708.
47. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, et al. (2006) p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66: 11432-11440.
48. Wessells J, Baer M, Young HA, Claudio E, Brown K, et al. (2004) BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 279: 49995-50003.
49. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, et al. (2009) Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proceedings of the National Academy of Sciences of the United States of America 106: 14978-14983.
50. Pena OM, Pistolic J, Raj D, Fjell CD, Hancock REW, (2011) Endotoxin Tolerance Represents a Distinctive State of Alternative Polarization (M2) in Human Mononuclear Cells. The Journal of Immunology 186: 7243-7254.
51. Bohuslav J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, et al. (1998) Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. The Journal of clinical investigation 102: 1645-1652.
52. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nature reviews Immunology 8: 958-969.